# FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class

> **Open Intelligence Dossier** · First detected: 2026-11-15 15:20 UTC · Category: Business

## Executive Summary
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.

## Intelligence Brief
According to reporting across multiple outlets including Bloomberg.com, Endpoints News, Yahoo Finance, Reuters, STAT, and Fierce Pharma, the United States Food and Drug Administration has officially declined to approve the lung cancer drug ivonescimab. The treatment, which is of Chinese origin and developed by Summit Therapeutics in partnership with Akeso, faced rejection in a narrow lung cancer setting. The regulatory decision halts the United States arrival of the much-hyped PD-1xVEGF class of therapies, creating a significant setback for the companies involved.


Coverage from the various news organizations heavily emphasizes the regulatory outcome and the specific circumstances surrounding the decision. Reuters explicitly notes that the federal agency declined the approval after a clinical trial missed a key survival goal, a detail mirrored across several analytical write-ups. Yahoo Finance published updates detailing the formal response from Summit Therapeutics regarding the Biologics License Application, while Fierce Pharma characterized the action as a direct derailment of the anticipated drug class introduction in the American market.


Context provided by the aggregated reports establishes that ivonescimab had generated substantial attention as a leading candidate within the novel PD-1xVEGF bispecific antibody category. The drug originated in China, bringing international development dynamics into the American regulatory spotlight. Because the therapeutic class has been generating considerable industry buzz, the refusal by the Food and Drug Administration represents a pivotal moment for pipeline evaluations across the pharmaceutical sector, shifting attention toward how developers will address missed trial endpoints in future regulatory submissions.


As coverage does not yet specify the full operational or financial fallout for Summit Therapeutics and Akeso beyond the immediate regulatory rebuff, stakeholders and observers will need to watch for forthcoming corporate announcements. Future updates from the companies will likely address whether they plan to amend their Biologics License Application, conduct additional clinical trials to satisfy regulatory demands, or pursue alternative pathways for the ivonescimab program in the United States and global markets.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| The New York Times | F.D.A. Rejects Closely Watched Lung Cancer Drug From China | [Source Link](https://news.google.com/rss/articles/CBMigAFBVV95cUxQOVd2cEJobjZyaWdnc0I5Q1Q0WEtQYW1WT2QxbHNJWGxPblJFZU42OHp0SkZrWWVKb18yY3h4Q1ZWM0phUmRvWVl0ZU1QbEtPdFdQc0ZfNnF1UlRiWWc2bUdWazh5N2ttRG1qY3BQUVdzMEJwcDRtRVNCdWlqS0NhaA?oc=5) |
| Financial Times | FDA rejects cancer drug invented in China in blow to Beijing’s biotech sector | [Source Link](https://news.google.com/rss/articles/CBMihAFBVV95cUxQSF81czliZUJkMnRRbzNpUENZS2NDTm5QNzd5UkI3Qk10R1hmcnIyNnJfQVY1SkJlZkJnc2RMUzhobDh5VTI4cUs2NjIwN3FPdVhHSV9taHRhaDBJWjlNZUFHLThTd01vZGZzVklhLVV4NlFOTlZZWjEzN2s4RW1peDF5N0w?oc=5) |
| Bloomberg.com | US FDA Rejects Summit’s China-Originated Lung Cancer Drug | [Source Link](https://news.google.com/rss/articles/CBMirAFBVV95cUxPelZQa1Q5Rk16X1ViWXNVRzZsX3YtOVU5R01FcThBUzlEME5HUHpMWnltbGFuTnEwaHdnOUpySllUUzczaF9SMGZGTVJuLVZ3U1Fvd2pNQ2c2YWhaMXVSWjdSWlJQQlVVZ2Q3Tm1OaEVXOGJUYV9qNWR1bnpTMkZkSXRpZEdjRG5fZDBGUEZHUUoyWVdldkxhX2FZbUZrMXFlWWtnUVBadkZVYXY2?oc=5) |
| Endpoints News | FDA rejects Summit, Akeso’s ivonescimab in narrow lung cancer setting | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxNaGJ6bF9CdnU4ajdVM1FBSThXN29RZG5sWkllOFlCeElqVy10SHJ5Mmk5Tjl3bU1qWjhKWFFNU3dfX1FVUlNDWnhwVnoxX0tTNUV1V2ZCTDJodUVzNV93ZmN3SGFmU2ppRDBheHNsMmpoREllNlZncEV0ZFBDSU9SZENXdjdYZ3BxSVE2dk9ldVJNVlhfeEE?oc=5) |
| Yahoo Finance | Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application | [Source Link](https://news.google.com/rss/articles/CBMisAFBVV95cUxQRmNodG9Ybmc4V3BqZTA0elNfemZia18zVE1wYnVPdnJHNzRZX2x4UEkyYk5NUzBKU19VUjF3enFYTzZnMWZUQ0FNSVJ0TGR4NzZfSkczWWxnbXRrVzl3bGQzaTJrQWhTQ1M0Q3ZrN21rSFM1Ny1qOXRyTEJlZG9IbmstTmd6S1YwTmRxQzlVMVJWdjJpbHVMUnQyMFFPTURGNzkzZGVDS3B3Nl9fQkxHVA?oc=5) |
| Reuters | US FDA declines to approve Summit lung cancer drug after trial misses key survival goal | [Source Link](https://news.google.com/rss/articles/CBMizAFBVV95cUxPSkdFR0ppNThGcnFUbE1vVHBkWG5GQkFrQ3B5M2x0VFh4bDNRVFdXUm9LazNYYUI4WnpBdXpQQ0NpS2llVWFEcE1LTWpLRWVqdFp4eTRibUtROW16ZU5XeXRmc1RwaTZCbzV2UXlKcEhvaHpCNlJSeTFucnl4ZXZvUWVWbXl2MUtHY1hXUzJ3SEFCR3ZZUDY2VGFuTC1lek80UmRZTGlxRkItd2I4S1lrcnotSF8tVG5tTnJySnBoMlJ0NXJtcEo5bjROV1c?oc=5) |
| STAT | FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics | [Source Link](https://news.google.com/rss/articles/CBMipAFBVV95cUxOZXFPV1FyNFd1Mm90OUJQdk9XajZya0tYVE1kSkV4RHhnZkMyM21KYzFRbzlQUmh2ZWE3MG5KR3NFQXJMcTNQY3lBYlZpRTV3V2lEcC0taUlvTm5zbHFSNi1RS0t4bTIxOGt4cGUzbGIwZllqUkZZeURVcF9rei1rUzhkMGZKaEU1djljSTljQXdKb2d2b1FDMVZoWng0YTJtbXJjdQ?oc=5) |
| Fierce Pharma | FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class | [Source Link](https://news.google.com/rss/articles/CBMimwFBVV95cUxPRUFJWnNTQ00yaXJYT21NN1BCMUdpM3BjbjdyUk9WOEFIcGx4U090RlVIbXp6OGVjTkFBREhGUnUtclFRU3d5OS1PVkVNQk9tZGVGSS1wZmNMamlleFBMalZUQzFrNXB5TGN5SzFMd3REcTZCcG5IQXpMMkFYc2lac0VEbnZ4V2NuSTZ4VVJrRnd6TkJfdUtJWmt6VQ?oc=5) |

---
*Canonical Source: https://pulse.byoaiapps.com/trend/2026-11-15/fda-rejects-summit-s-ivonescimab-derailing-us-arrival-of-much-hyped-pd-1xvegf*
